Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

[1]  O. Delattre,et al.  Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Lim,et al.  Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1 , 2021, Blood.

[3]  K. Wilner,et al.  Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) , 2021, Clinical Cancer Research.

[4]  K. Wilner,et al.  Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212) , 2020, Cancer Chemotherapy and Pharmacology.

[5]  U. Tateishi,et al.  Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial , 2020, Cancer science.

[6]  S. Armstrong,et al.  Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. , 2020, European journal of cancer.

[7]  K. Norga,et al.  Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Gambacorti-Passerini,et al.  Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy , 2020, American journal of hematology.

[9]  A. Attarbaschi,et al.  Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. MacKenzie,et al.  CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma , 2020, British Journal of Cancer.

[11]  K. Norga,et al.  Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. , 2020, European journal of cancer.

[12]  S. Groshen,et al.  Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study. , 2020 .

[13]  M. Fischer,et al.  Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK). , 2020 .

[14]  C. E. van der Schoot,et al.  Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma , 2020, JCO precision oncology.

[15]  David T. W. Jones,et al.  Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. , 2020, Cancer discovery.

[16]  A. Ferrari,et al.  Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). , 2020, European journal of cancer.

[17]  A. Jenkner,et al.  ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. , 2020, European journal of cancer.

[18]  A. Clayton,et al.  Uterine inflammatory Myofibroblastic tumors in pregnant women with and without involvement of the placenta: a study of six cases with identification of a novel TIMP3-RET fusion. , 2020, Human pathology.

[19]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[20]  Edward S. Kim,et al.  Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Arun K. Ramani,et al.  Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.

[22]  T. Mercer,et al.  Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors , 2019, JCO precision oncology.

[23]  Daniel Martinez,et al.  An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma , 2019, Science Translational Medicine.

[24]  W. Klapper,et al.  ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. , 2019, European journal of cancer.

[25]  O. Delattre,et al.  Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis , 2018, International journal of cancer.

[26]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[27]  J. Blay,et al.  Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. , 2018, The Lancet. Respiratory medicine.

[28]  S. Bielack,et al.  Inflammatory myofibroblastic tumors—A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe , 2018, Pediatric blood & cancer.

[29]  Hongyu Zhao,et al.  Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma. , 2018, Oncology letters.

[30]  Chunxu Qu,et al.  Targeting ALK in pediatric RMS does not induce antitumor activity in vivo , 2018, Cancer Chemotherapy and Pharmacology.

[31]  H. Aburatani,et al.  Integrated molecular profiling of juvenile myelomonocytic leukemia. , 2018, Blood.

[32]  K. Bochennek,et al.  Crizotinib in ALK+ inflammatory myofibroblastic tumors—Current experience and future perspectives , 2018, Pediatric blood & cancer.

[33]  J. Ahn,et al.  Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study , 2018, American journal of hematology.

[34]  O. Delattre,et al.  Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma , 2017, Clinical Cancer Research.

[35]  P. D. Dal Cin,et al.  Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma , 2017, JAMA oncology.

[36]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  M. Lim,et al.  Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  P. Stephens,et al.  Identification of NTRK fusions in pediatric mesenchymal tumors , 2017, Pediatric blood & cancer.

[39]  P. Raman,et al.  Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome , 2016, PLoS genetics.

[40]  S. Robinson,et al.  The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN , 2016, Disease Models & Mechanisms.

[41]  C. Strahlendorf,et al.  ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors , 2016, The American journal of surgical pathology.

[42]  Y. Oda,et al.  ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours , 2016, Histopathology.

[43]  C. Gambacorti-Passerini,et al.  Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. , 2016, The New England journal of medicine.

[44]  I. Lax,et al.  Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions , 2015, Proceedings of the National Academy of Sciences.

[45]  Y. Mossé,et al.  Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies , 2015, Clinical Cancer Research.

[46]  P. Raman,et al.  Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma , 2015, Clinical Cancer Research.

[47]  R. Palmer,et al.  FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase , 2015, eLife.

[48]  M. Ahn,et al.  Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer , 2015, PLoS genetics.

[49]  C. Antonescu,et al.  Molecular Characterization of Inflammatory Myofibroblastic Tumors With Frequent ALK and ROS1 Gene Fusions and Rare Novel RET Rearrangement , 2015, The American journal of surgical pathology.

[50]  Gudrun Schleiermacher,et al.  Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations , 2015, Nature Genetics.

[51]  Lynette M. Smith,et al.  Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group , 2014, Pediatric Blood & Cancer.

[52]  Ravi Radhakrishnan,et al.  ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. , 2014, Cancer cell.

[53]  F. Speleman,et al.  Emergence of new ALK mutations at relapse of neuroblastoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[55]  P. Stephens,et al.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. , 2014, Cancer discovery.

[56]  H. Ohno,et al.  Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)–anaplastic lymphoma kinase (ALK) acute myeloid leukemia , 2014, Leukemia.

[57]  L. Guerra,et al.  Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. , 2014, Journal of the National Cancer Institute.

[58]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[59]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[60]  J. Orange,et al.  Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma , 2012, Oncogene.

[61]  N. Santoro,et al.  Results of AIEOP LNH‐97 protocol for the treatment of anaplastic large cell lymphoma of childhood , 2012, Pediatric blood & cancer.

[62]  W. Klapper,et al.  Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  Wei-Lien Wang,et al.  Epithelioid Inflammatory Myofibroblastic Sarcoma: An Aggressive Intra-abdominal Variant of Inflammatory Myofibroblastic Tumor With Nuclear Membrane or Perinuclear ALK , 2011, The American journal of surgical pathology.

[64]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[65]  Frank Speleman,et al.  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.

[66]  Patrick Lutz,et al.  Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  S. Perkins,et al.  Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941 , 2009, Pediatric blood & cancer.

[68]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[69]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[70]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[71]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[72]  B. Burkhardt,et al.  Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin–Frankfurt–Münster group report , 2006, British journal of haematology.

[73]  M. Pillon,et al.  Anaplastic large cell lymphoma treated with a leukemia‐like therapy , 2005, Cancer.

[74]  N. Tarbell,et al.  Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Y. Yamashita,et al.  ALK+, CD30−, CD20− Large B-Cell Lymphoma Containing Anaplastic Lymphoma Kinase (ALK) Fused to Clathrin Heavy Chain Gene (CLTC) , 2003, Modern Pathology.

[76]  C. R. Pinkerton,et al.  Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children's Cancer Study Group chemotherapy regimens , 2002, British journal of haematology.

[77]  M. Tiemann,et al.  Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. , 2001, Blood.

[78]  G. Leverger,et al.  Anaplastic Large-Cell Lymphoma in Children : Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology , 1998 .

[79]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[80]  W. Feng,et al.  Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. , 2019, The Lancet. Respiratory medicine.

[81]  H. Zou,et al.  A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Alk/ros1 Inhibitor Pf-06463922 Overcomes Primary Resistance to Crizotinib in Alk-driven Neuroblastoma , 2022 .

[82]  Roberto Piva,et al.  The anaplastic lymphoma kinase in the pathogenesis of cancer , 2008, Nature Reviews Cancer.